Compare OVBC & ENTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | OVBC | ENTA |
|---|---|---|
| Founded | 1872 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 188.7M | 374.6M |
| IPO Year | 1996 | 2012 |
| Metric | OVBC | ENTA |
|---|---|---|
| Price | $42.21 | $12.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $20.40 |
| AVG Volume (30 Days) | 8.0K | ★ 141.5K |
| Earning Date | 04-24-2026 | 05-11-2026 |
| Dividend Yield | ★ 2.18% | N/A |
| EPS Growth | ★ 42.67 | 29.93 |
| EPS | ★ 3.31 | N/A |
| Revenue | N/A | ★ $102,814,000.00 |
| Revenue This Year | N/A | $7.76 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.77 | ★ N/A |
| Revenue Growth | N/A | ★ 16.48 |
| 52 Week Low | $25.75 | $4.09 |
| 52 Week High | $44.80 | $17.15 |
| Indicator | OVBC | ENTA |
|---|---|---|
| Relative Strength Index (RSI) | 51.85 | 39.83 |
| Support Level | $39.07 | $12.09 |
| Resistance Level | $43.26 | $15.52 |
| Average True Range (ATR) | 1.25 | 0.76 |
| MACD | 0.05 | -0.13 |
| Stochastic Oscillator | 69.80 | 8.70 |
Ohio Valley Banc Corporation is a financial holding company. The bank is a full-service financial institution offering a blend of commercial and consumer banking services within Southeastern Ohio as well as western West Virginia. The banking services offered by the bank include the acceptance of deposits in checking, savings, time and money market accounts; the making and servicing of personal, commercial, and student loans; and the making of construction and real estate loans. It also offers individual retirement accounts, safe deposit boxes, wire transfers and other standard banking products and services.
Enanta Pharmaceuticals Inc is a biotechnology company that uses a chemistry-based drug discovery approach to develop small-molecule candidates for virology and immunology applications. It focuses on Virology and Immunology. Its active development programs in virology are focused on respiratory syncytial virus, or RSV, and SARS-CoV-2, and Hepatitis B virus. In immunology, the company is engaged in designing and developing potent and selective, oral small molecule inhibitors for the treatment of type 2 inflammatory disease. The company has collaborated with AbbVie, which markets its protease inhibitor paritaprevir, with additional inhibitors in development. The company generates the majority revenue in the form of royalty revenue.